Australia's Therapeutic Goods Administration (TGA) has added important safety warnings for certain diabetes and weight loss drugs. The TGA warns about suicidal thoughts and behaviour linked to the GLP-1 receptor agonists class of medicines, which includes Ozempic, Wegovy, Saxenda, Trulicity, and Mounjaro. Doctors should “monitor patients for the emergence or worsening of depression, suicidal thoughts or behaviours, and/or any unusual changes in mood or behaviour.” The TGA also issued a separate warning about Mounjaro and contraception. They found a possible risk that oral contraceptives may be less effective when starting or increasing the dose of Mounjaro. As a safety step, the product label now advises patients using oral contraceptives to switch to a non-oral method or add a barrier method for four weeks after starting or increasing the Mounjaro dose. Additionally, the TGA said none of the GLP-1 receptor agonists should be used during pregnancy.